<DOC>
	<DOCNO>NCT00206700</DOCNO>
	<brief_summary>The purpose study establish safety profile sargramostim administer 8 week cycle adult patient active Crohn 's disease .</brief_summary>
	<brief_title>Open-label Trial Leukine Active Crohn 's Disease</brief_title>
	<detailed_description>On 29 May 2009 , Bayer begin transition sponsorship trial Genzyme . NOTE : This study originally post sponsor Berlex , Inc. Berlex , Inc. rename Bayer HealthCare , Inc .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Molgramostim</mesh_term>
	<criteria>Able provide inform consent Participated previous study sargramostim Crohn 's disease within past 12 month Subjects participate protocol exclude concomitant steroid use : Must moderately severely active Crohn 's disease time screen ( CDAI score &gt; /= 220 point less equal 475 point ) Must receive less equal 40 mg prednisone ( equivalent ) daily time screen treated corticosteroid complete previous sargramostim study entry study able taper less equal 7.5 mg daily within one treatment cycle Subjects participate Protocol 307501 Must active Crohn 's disease ( CDAI score &gt; 150 point less equal 450 point ) completely withdraw CS use Must receive less equal 40 mg prednisone ( equivalent ) daily time screening , able taper less equal 7.5 mg daily within 2 treatment cycle , CDAI score less equal 450 point completely withdraw CS use Have negative serum pregnancy test within 2 week prior receive initial dose sargramostim female subject childbearing potential ( optional may waive investigator subject interruption contraception method since participation previous study ) Agree use adequate method contraception throughout study period sexuallyactive male female childbearing potential Able selfinject sargramostim designee Able comply protocol requirement Have negative stool exam subject receive course antibiotic since participation previous study Pregnant breastfeed female Need gastrointestinal ( GI ) surgery active GI bleeding , peritonitis , intestinal obstruction , intraabdominal perianal abscess require surgical drainage Gastrointestinal surgery within prior 6 month Symptoms bowel obstruction confirm evidence clinicallysignificant stricture within last 6 month surgically correct Serum creatinine great equal 2.0 mg/dL Alkaline phosphatase ( ALP ) , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , total bilirubin great equal 2X upper limit normal ; hemoglobin ( Hb ) &lt; 8.0 gm/dL ; platelet count great equal 800,000/mL ; ANC le equal 1,000/µL &gt; 20,000/µL ( exclusion subject ANC &gt; 20,000/µL applies entry first treatment cycle ) Use licensed/registered antitumor necrosis factor ( TNF ) therapy infliximab within 8 week prior first dose study drug trial Use follow medication within 4 week prior receive first dose study drug : 6mercaptopurine , azathioprine , cyclophosphamide , methotrexate , mycophenolate mofetil , tacrolimus , cyclosporine , thalidomide Use experimental agent clinical trial since participate sargramostim trial History allergy yeast product sargramostim Psychiatric illness substance abuse would interfere ability comply protocol requirement give informed consent Clinically important primary disease unrelated Crohn 's disease Prior exposure natalizumab ( Tysabri )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>